These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35404670)

  • 1. Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure : A Systematic Review and Meta-analysis.
    Zou X; Shi Q; Vandvik PO; Guyatt G; Lang CC; Parpia S; Wang S; Agarwal A; Zhou Y; Zhu Y; Tian H; Zhu Z; Li S
    Ann Intern Med; 2022 Jun; 175(6):851-861. PubMed ID: 35404670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    ;
    Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
    BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
    Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
    Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis.
    Bhattarai M; Salih M; Regmi M; Al-Akchar M; Deshpande R; Niaz Z; Kulkarni A; Siddique M; Hegde S
    JAMA Netw Open; 2022 Jan; 5(1):e2142078. PubMed ID: 34985519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
    Neuen BL; Oshima M; Agarwal R; Arnott C; Cherney DZ; Edwards R; Langkilde AM; Mahaffey KW; McGuire DK; Neal B; Perkovic V; Pong A; Sabatine MS; Raz I; Toyama T; Wanner C; Wheeler DC; Wiviott SD; Zinman B; Heerspink HJL
    Circulation; 2022 May; 145(19):1460-1470. PubMed ID: 35394821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis.
    Pandey AK; Dhingra NK; Hibino M; Gupta V; Verma S
    ESC Heart Fail; 2022 Apr; 9(2):942-946. PubMed ID: 35112512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
    Hinton W; Ansari AS; Whyte MB; McGovern AP; Feher MD; Munro N; de Lusignan S
    Diabetes Obes Metab; 2023 Feb; 25(2):501-515. PubMed ID: 36239122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
    Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
    Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
    JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Mori Y; Duru OK; Tuttle KR; Fukuma S; Taura D; Harada N; Inagaki N; Inoue K
    J Clin Endocrinol Metab; 2022 Dec; 108(1):221-231. PubMed ID: 36217306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
    Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
    Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review.
    Rådholm K; Wu JH; Wong MG; Foote C; Fulcher G; Mahaffey KW; Perkovic V; Neal B
    Diabetes Res Clin Pract; 2018 Jun; 140():118-128. PubMed ID: 29604389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: A systematic review and meta-analysis of randomized controlled trials and cohort studies.
    Huang X; Dannya E; Liu X; Yu Y; Tian P; Li Z
    Diabetes Obes Metab; 2024 Mar; 26(3):1040-1049. PubMed ID: 38086546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.